The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study
Open accessAbstract
The aim of the present study was to test whether the combination of a beta-lactam drug plus an aminoglycoside has advantage over monotherapy for severe gram-negative infections. Of 2,124 patients with gram-negative bacteremia surveyed prospectively, 670 were given inappropriate empirical antibiotic treatment and the mortality rate in this group was 34%, whereas the mortality rate was 18% for 1,454 patients given appropriate empirical antibiotic treatment (P = 0.0001). The mortality rates for patients given appropriate empirical antibiotic treatment were 17% for 789 patients given a single beta-lactam drug, 19% for 327 patients given combination treatment, 24% for 249 patients given a single aminoglycoside, and 29% for 89 patients given other antibiotics (P = 0.0001). When patients were stratified according to risk factors for mortality other than antibiotic treatment, combination therapy showed no advantage over treatment with a single beta-lactam drug except for neutropenic patients (odds ratio [OR] for mortality, 0.5; 95% confidence interval [95% CI], 0.2 to 1.3) and patients with Pseudomonas aeruginosa bacteremia (OR, 0.7; 95% CI, 0.3 to 1.8). On multivariable logistic regression analysis including all risk factors for mortality, combination therapy had no advantage over therapy with a single beta-lactam drug. The mortality rate for patients treated with a single appropriate aminoglycoside was higher than that for patients given a beta-lactam drug in all strata except for patients with urinary tract infections. When the results of blood cultures were known, 1,878 patients were available for follow-up. Of these, 816 patients were given a single beta-lactam drug, 442 were given combination treatment, and 193 were given a single aminoglycoside. The mortality rates were 13, 15, and 23%, respectively (P = 0.0001). Both on stratified and on multivariable logistic regression analyses, combination treatment showed a benefit over treatment with a single beta-lactam drug only for neutropenic patients (OR, 0.2; 95% CI, 0.05 to 0.7). In summary, combination treatment showed no advantage over treatment with an appropriate beta-lactam drug in nonneutropenic patients with gram-negative bacteremia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotics in Laboratory Medicine.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,779
Hilf, M., Yu, V. L., Sharp, J., Zuravleff, J. J., Korvick, J. A., & Muder, R. R. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90695-5 · Cited by 563
Risk factors and outcome of hospital-acquired acute renal failure
Shusterman, N., Strom, B. L., Murray, T. G., Morrison, G., West, S. L., & Maislin, G. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90498-0 · Cited by 367
Bryan, C. S., Reynolds, K. L., & Brenner, E. R. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.4.629 · Cited by 360
The EORTC International Antimicrobial Therapy Cooperative Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198712313172703 · Cited by 345
Long-term Survival and Function After Suspected Gram-negative Sepsis
Perl, T. M. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530040066043 · Cited by 300
Korvick, J. A., Bryan, C. S., Farber, B., Beam, T. R., Schenfeld, L., Muder, R. R., Weinbaum, D., Lumish, R., Gerding, D. N., & Wagener, M. M. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2639 · Cited by 212
Long-term Survival Following Bacteremia or Fungemia
Leibovici, L. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530100047033 · Cited by 166
Self-citationGiamarellou, H. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90490-0 · Cited by 118
Hoepelman, I. M., Rozenberg-Arska, M., & Verhoef, J. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92121-6 · Cited by 42
Cited by
Dellit, T. H., Owens, R. C., McGowan, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O., Carpenter, C. F., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510393 · Cited by 3,362
Ventilator-associated Pneumonia
Chastre, J., & Fagon, J.-Y. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.7.2105078 · Cited by 2,812
Ibrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779
Kumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J. E., Dodek, P., Wood, G., Kumar, A., Simon, D., et al. (2009) · Chest · doi:10.1378/chest.09-0087 · Cited by 1,187
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Kang, C.-I., Kim, S.-H., Park, W. B., Lee, K.-D., Kim, H.-B., Kim, E.-C., Oh, M.-D., & Choe, K.-W. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.760-766.2005 · Cited by 692
Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized Patients
Kollef, M. H. (2000) · Clinical Infectious Diseases · doi:10.1086/314079 · Cited by 635
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
Antibiotic Resistance in the Intensive Care Unit
Kollef, M. H., & Fraser, V. J. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-4-200102200-00014 · Cited by 478
Paul, M., Benuri-Silbiger, I., Soares-Weiser, K., & Leibovici, L. (2004) · BMJ · doi:10.1136/bmj.38028.520995.63 · Cited by 466
Self-citationSafdar, N., Handelsman, J., & Maki, D. G. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01108-9 · Cited by 417
Ventilator-Associated Pneumonia
(2012) · SpringerReference · doi:10.1007/springerreference_225126 · Cited by 406
Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa
Rossolini, G. M., & Mantengoli, E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01161.x · Cited by 395
Paul, M., Lador, A., Grozinsky-Glasberg, S., & Leibovici, L. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003344.pub3 · Cited by 377
Self-citationNguyen, H. B., Rivers, E. P., Abrahamian, F. M., Moran, G. J., Abraham, E., Trzeciak, S., Huang, D. T., Osborn, T., Stevens, D., & Talan, D. A. (2006) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2006.02.015 · Cited by 356
Kumar, A., Safdar, N., Kethireddy, S., & Chateau, D. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e96b91 · Cited by 340
Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary
Chow, J. W., & Yu, V. L. (1999) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(98)00060-0 · Cited by 320
Zavascki, A. P., Carvalhaes, C. G., Picão, R. C., & Gales, A. C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.108 · Cited by 312
Defining, treating and preventing hospital acquired pneumonia: European perspective
Torres, A., Ewig, S., Lode, H., Carlet, J., & For The European HAP working group (2009) · Intensive Care Medicine · doi:10.1007/s00134-008-1336-9 · Cited by 298
Micek, S. T., Welch, E. C., Khan, J., Pervez, M., Doherty, J. A., Reichley, R. M., & Kollef, M. H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01365-09 · Cited by 278
Pneumonia Due to Pseudomonas aeruginosa
Fujitani, S., Sun, H.-Y., Yu, V. L., & Weingarten, J. A. (2011) · Chest · doi:10.1378/chest.10-0166 · Cited by 273
Paul, M., Soares-Weiser, K., & Leibovici, L. (2003) · BMJ · doi:10.1136/bmj.326.7399.1111 · Cited by 267
Self-citationColistin: new lessons on an old antibiotic
Yahav, D., Farbman, L., Leibovici, L., & Paul, M. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03734.x · Cited by 259
Self-citation
Metadata
- Authors
- Leibovici, L., Paul, M., Poznanski, O., Drucker, M., Samra, Z., Konigsberger, H., & Pitlik, S. D.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-05
- Volume
- 41
- Issue
- 5
- Pages
- 1127-1133
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2156920884
- Cited by
- 280
- References
- 11
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.